Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy
- 192 Downloads
Although users of aromatase inhibitors have higher total fracture risk in some randomized trials, little is known about their risk outside of clinical trials or in older higher-risk cohorts.
In a population-based retrospective cohort study, we identified all older US Medicare D prescription drug insurance plan-enrolled women who had initial breast cancer surgery in 2006–2008 and began hormonal therapy (an aromatase inhibitor (AI) or tamoxifen) within the subsequent year. Total nonvertebral and hip fractures through 2012 were identified using a validated algorithm. The association of fracture outcomes with hormonal therapy type was assessed using competing risk regression models that accounted for differences in measured baseline covariates. Treatment assignment bias was reduced using inverse probability of treatment weighting computed from propensity scores.
Among 23,378 women taking hormonal therapy (23.2% aged 80 or over), there were 3000 total and 436 hip fractures. Although AI users were younger and had lower comorbidity, after propensity score weighting, these and other covariates were balanced. Total nonvertebral risk was higher for users of AIs compared with tamoxifen, HR 1.11 (1.02–1.21), but the small increase in risk for hip fracture was not statistically significant, HR 1.04 (0.84–1.30).
Although total nonvertebral fracture risk was higher among AI users, differences in hip fractures were not significant in a large population-based cohort of older women.
Implications for Cancer Survivors
Use of aromatase inhibitors by older women is associated with high risk for nonvertebral fracture that is increased compared with use of tamoxifen. Fracture risk should be assessed among patients taking these medications.
KeywordsBreast cancer Hormone therapy Fracture Population based Post-menopausal
The study was funded by the American Cancer Society (RSG-11-098-01-CPHPS to JMN).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required. This article does not contain any studies with animals performed by any of the authors.
- 2.Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60–2. https://doi.org/10.1016/S0140-6736(04)17666-6.CrossRefPubMedGoogle Scholar
- 6.Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol. 2011;12(12):1101–8. https://doi.org/10.1016/S1470-2045(11)70270-4.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042–57. https://doi.org/10.1200/JCO.2003.08.017.CrossRefPubMedGoogle Scholar
- 9.Kolata G. Bone diagnosis gives new data but no answers. The New York Times 2003 September 28.Google Scholar
- 11.Neuner JM, Kamaraju S, Charlson JA, Wozniak EM, Smith EC, Biggers A, et al. The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees. J Natl Can Inst. 2015;107(8) https://doi.org/10.1093/jnci/djv130.
- 18.National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington D.C.: National Osteoporosis Foundation 2014.Google Scholar
- 20.Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, et al. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat. 2014;145(2):491–501. https://doi.org/10.1007/s10549-014-2968-9.CrossRefPubMedGoogle Scholar
- 25.Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922):1041–8. https://doi.org/10.1016/S0140-6736(13)62292-8.CrossRefPubMedGoogle Scholar
- 27.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Breast Cancer. 2016;Google Scholar
- 28.Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18(8):1033–46. https://doi.org/10.1007/s00198-007-0343-y.CrossRefPubMedGoogle Scholar